About: http://data.cimple.eu/news-article/35130ab768e504be7139f09d3686529300516a1db5fc70bc65f86666

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/35130ab768e504be7139f09d3686529300516a1db5fc70bc65f86666 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	Novavax's Covid-19 jab is more than 90 percent effective, including against coronavirus variants, the vaccine maker said Monday after a large-scale US study. The jab "demonstrated 100% protection against moderate and severe disease, 90.4% efficacy overall," the company said in a statement, adding "the study enrolled 29,960 participants across 119 sites in the U.S. and Mexico to evaluate efficacy, safety and immunogenicity." The Maryland-headquartered company said it intended to apply for regulatory approval by the third quarter of 2021. After that, it said, it would be on course to make 100 million doses per month by the end of the third quarter and 150 million doses per month by the end of the year. "Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines," said Stanley C. Erck, Novavax's president and chief executive. "Novavax continues to work with a sense of urgency to complete our regulatory submissions and deliver this vaccine, built on a well understood and proven platform, to a world that is still in great need of vaccines." While some rich countries have made progress on vaccinating their populations, there remain concerns that many poorer countries are being left out of the global inoculation drive. Vaccination rates in the world's poorest nations are far behind the Group of Seven industrialized powers and other wealthy states -- in terms of doses administered so far, the imbalance between the G7 and the planet's low-income countries, as defined by the World Bank, is 73 to one. Unlike some rival jabs, Novavax's vaccine -- formally known as NVX-CoV2373 -- does not have to be stored at ultra-low temperatures. The company said it was "stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution." In theory at least, this means the shots should be more easily transported and administered in countries with less well developed health infrastructures. bur-leg/reb
schema:headline	Covid-19 vaccine more than 90 percent effective: Novavax
schema:mentions	Novavax Inoculation Supply chain Seven Network Group of Seven Public health Jab World Bank Planet Vaccination Mexico Vaccine Severe acute respiratory syndrome coronavirus 2 Coronavirus disease 2019 Immunogenicity
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2021-06-14 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	positive sentiment
http://data.cimple...readability_score	80 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software